For instance, NHS-muIL12 monotherapy (therapies 2 and 3) led to a substantial increase in the fitted ε compared to the Isotype Control (therapy 1), suggesting a tumor counter-adaptation by upregulating PD-L1 in response to enhanced immune stimulation. The gene discussed is CD274; the disease is neoplasm.